Journal Article10.1200/JCO.2013.31.15_SUPPL.4503
Characterization of relapse in patients with clinical stage I (CSI) nonseminoma (NS-TC) managed with active surveillance (AS): A large multicenter study.
Christian K. Kollmannsberger,Torgrim Tandstad,Philippe L. Bedard,Michael A.S. Jewett,Gabriella Cohn-Cedermark,Peter Chung,Gedske Daugaard,Padraig Warde,Malcolm J. Moore,Craig R. Nichols +9 more
4
TL;DR: Large single institution trials have demonstrated that AS for patients with CSI NS-TC is safe and effective, and information on timing and extent of relapse following AS has the potent drug-like properties.
read more
Abstract: 4503 Background: Large single institution trials have demonstrated that AS for patients with CSI NS-TC is safe and effective. Information on timing and extent of relapse following AS has the potent...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Testicular Cancer: A Reflection on 50 Years of Discovery
TL;DR: The basic tenets of cancer care were established, reinforced, or challenged during the methodical study of testicular cancer include the use of randomized clinical trials to minimize toxicity and maximize outcomes; the rational utilization of combination chemotherapy; and the integration of care involving medical and surgical specialties.
153
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer
Jan Oldenburg,Jan Oldenburg,Jorge Aparicio,Jörg Beyer,Gabriella Cohn-Cedermark,Michael Cullen,Timothy D. Gilligan,U. De Giorgi,M. De Santis,R. de Wit,Sophie D. Fosså,J. R. Germa-Lluch,Silke Gillessen,Hege Sagstuen Haugnes,Friedemann Honecker,Alan Horwich,Anja Lorch,D. Ondruš,Giovanni Rosti,Andrew J. Stephenson,T. Tandstad +20 more
TL;DR: An overview about risk factors for relapse, potential benefits and harms of adjuvant chemotherapy and active surveillance and a rationale for involving patients in individualized decision making about their treatment rather than adopting a uniform recommendation for all are provided.
69
Management of clinical stage I nonseminomatous germ cell tumors
Sumit Isharwal,Michael C. Risk +1 more
TL;DR: All three treatment modalities have similar survival rates approaching 100% but differing potential morbidities, which, along with patient preferences and compliance, should guide treatment decisions.
8
Update Erstlinien- und Rezidivchemotherapie beim Hodentumor
TL;DR: In this paper, the authors focus on the treatment of Keimzelltumoren, a group of patients who suffer from the haufigste Tumorerkrankung in the world.
3